HIV Infections Clinical Trial
Official title:
Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women by SisterLove, Inc. in Atlanta, GA
The purpose of this program evaluation is to determine whether the Health Love Workshop, a group-level HIV behavioral intervention, reduces HIV-related sex risk behaviors and increases HIV protective behaviors of African American women and women of African descent. The intent of this program is to support an evaluation of the efficacy of the intervention and to provide feedback to the implementing organization to increase intervention effectiveness.
SisterLove, Inc. in Atlanta, Georgia, is evaluating its HIV/AIDS prevention intervention
called the Healthy Love Workshop (HLW). The HLW targets African American women and women of
African descent who are at risk for HIV infection and transmission. The HLW, which lasts 3
to 4 hours and is delivered during a single session, is a highly interactive workshop that
aims to provide a safe environment in which women can learn about: a) the modes of HIV
transmission, b) effective strategies for reducing one's risk for contracting or
transmitting HIV or other STIs, c) opportunities to develop or enhance skills for
self-assessing the risk level of sexual behaviors and the use of safer sex techniques, and
d) how to develop an awareness of personal, community and social attitudes, beliefs and
norms that influence women's relationships, sexual behavior, and decision-making. SisterLove
will identify a minimum of 28 groups of women to participate in the evaluation, which will
use a concurrent comparison design with block randomization. These groups will be typical of
those that currently receive the HLW, including but not limited to sororities, friendship
circles, church groups and other affinity-based groups. Fourteen of the 28 groups will
participate in HLW as the intervention group; 14 of the recruited groups will participate in
an HIV/AIDS 101 workshop (HIV 101) as the comparison group. Each group will contain about 15
women, thus approximately 420 women will participate in the evaluation. Outcome measures
will assess HIV/AIDS knowledge, attitudes towards condom use and HIV testing, condom use
intentions, personal HIV/AIDS risk assessment, self-efficacy for taking steps to prevent HIV
transmission, consistent condom use, sexual abstinence, and reduction in other sexual risk
behaviors. These outcomes will be measured at baseline, and after the intervention at 3- and
6-month follow-ups.
Eligible groups of women were randomly assigned to receive the intervention (15 groups; 161
women) or a comparison workshop (15 groups; 152 women). Behavioral assessments were
conducted at baseline and at 3- and 6-month follow-ups. Among sexually active women at the
3-month follow-up, HLW participants were more likely than comparison participants to report
having used condoms during vaginal sex with any male partner or with a primary male partner,
and to have used condoms at last vaginal, anal or oral sex with any male partner. At the
6-month follow-up, HLW participants were more likely to report condom use at last vaginal,
anal or oral sex with any male partner, and having an HIV test and receiving their test
results. The study findings suggest that a single-session intervention delivered to
pre-existing groups of black women is an efficacious approach to HIV prevention. This study
also demonstrates that a CBO can develop and deliver a culturally appropriate, effective HIV
prevention intervention for the population it serves and, with adequate resources and
technical assistance, rigorously evaluate its intervention.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |